Drug intelligence / Profile preview

SC-005

Development stage: Discontinued
Lead developer: AbbVie
Modality: Small Molecules, Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
Administration: Intravenous

Overview

SC-005 is an antibody-drug conjugate (ADC) developed by AbbVie for the treatment of triple negative breast cancer. It consists of a proprietary monoclonal antibody targeting a tumor-associated antigen, linked to an undisclosed cytotoxic agent, and was designed to deliver targeted antineoplastic activity. The precise mechanism of action and molecular target have not been publicly disclosed. Clinical development reached phase 1 trials in the United States but was discontinued due to strategic considerations[1][2][3][5].

Other names: Antibody-drug conjugate SC-005

Targets

MELTF (Melanotransferrin)

Beyond the preview

Go deeper on SC-005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SC-005.

Explore the full profile